Evidence map›Paper›PMID 35761398›Full record

ArticleCell communication and signaling : CCS2022

Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells.

Arindam Mondal, Jacques Roberge, John Gilleran, Youyi Peng, Dongxuan Jia, Moumen Akel, Yash Patel, Harrison Zoltowski, Anupama Doraiswamy, John Langenfeld

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Cell communication and signaling : CCS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. BMP signaling in cancer stemness and differentiation.Cell regeneration (London, England) · 2023
    Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Arindam MondalDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 1 Robert Wood Johnson Place, New Brunswick, NJ, 08903, USA.
Jacques RobergeMolecular Design and Synthesis, RUBRIC, Office for Research, Rutgers Translational Science, Rutgers University, Piscataway, NJ, 08854, USA.
John GilleranMolecular Design and Synthesis, RUBRIC, Office for Research, Rutgers Translational Science, Rutgers University, Piscataway, NJ, 08854, USA.
Youyi PengBiomedical Informatics Shared Resources, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08903, USA.
Dongxuan JiaDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 1 Robert Wood Johnson Place, New Brunswick, NJ, 08903, USA.
Moumen AkelRutgers University, Piscataway, NJ, 08854, USA.
Yash PatelRutgers University, Piscataway, NJ, 08854, USA.
Harrison ZoltowskiRutgers University, Piscataway, NJ, 08854, USA.
Anupama DoraiswamyCancer Institute of New Jersey, New Brunswick, NJ, USA.
John LangenfeldDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 1 Robert Wood Johnson Place, New Brunswick, NJ, 08903, USA. langenje@cinj.rutgers.edu.
Rutgers, The State University of New Jersey · USJohnson University · USCancer Institute of Florida · USRutgers Cancer Institute of New Jersey

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Targeting BMP type 2 receptor for the treatment of breast cancer.R01CA225830 · NCI · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI LANGENFELD, JOHN · 2018 to 2022
$3.2M
Supercomputing: Rutgers' Catalyst for Discovery at the Frontiers of MedicineS10OD012346 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI MICHELSON, LESLIE PAUL · 2015 to 2015
$1.7M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA225830NIH HHS S10 OD012346
6 · The paper itself

Abstract

backgroundBone morphogenetic proteins (BMP) are evolutionarily conserved morphogens that are reactivated in lung carcinomas. In lung cancer cells, BMP signaling suppresses AMP activated kinase (AMPK) by inhibiting LKB1. AMPK is activated by mitochondrial stress that inhibits ATP production, which is enhanced 100-fold when phosphorylated by LKB1. Activated AMPK can promote survival of cancer cells but its "hyperactivation" induces cell death. The studies here reveal novel cell death mechanisms induced by BMP inhibitors, together with agents targeting the mitochondria, which involves the "hyperactivation" of AMPK.

methodsThis study examines the synergistic effects of two BMP inhibitors together with mitochondrial targeting agents phenformin and Ym155, on cell death of lung cancer cells expressing LKB1 (H1299), LKB1 null (A549), and A549 cells transfected with LKB1 (A549-LKB1). Cell death mechanisms evaluated were the activation of caspases and the nuclear localization of apoptosis inducing factor (AIF). A769662 was used to allosterically activate AMPK. Knockdown of BMPR2 and LKB1 using siRNA was used to examine their effects on nuclear localization of AMPK. Validation studies were performed on five passage zero primary NSCLC.

resultsBoth BMP inhibitors synergistically suppressed growth when combined with Ym155 or phenformin in cells expressing LKB1. The combination of BMP inhibitors with mitochondrial targeting agents enhanced the activation of AMPK in lung cancer cells expressing LKB1. Allosteric activation of AMPK with A769662 induced cell death in both H1299 and A549 cells. Cell death induced by the combination of BMP inhibitors and mitochondrial-targeting agents did not activate caspases. The combination of drugs induced nuclear localization of AIF in cells expressing LKB1, which was attenuated by knockdown of LKB1. Knockdown of BMPR2 together with Ym155 increased nuclear localization of AIF. Combination therapy also enhanced cell death and AIF nuclear localization in primary NSCLC.

conclusionsThese studies demonstrate that inhibition of BMP signaling together with mitochondrial targeting agents induce AIF caspase-independent cell death, which involves the "hyperactivation" of AMPK. AIF caspase-independent cell death is an evolutionarily conserved cell death pathway that is infrequently studied in cancer. These studies provide novel insight into mechanisms inducing AIF caspase-independent cell death in cancer cells using BMP inhibitors. Video Abstract.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAMP-Activated Protein KinasesApoptosisApoptosis Inducing FactorBone Morphogenetic ProteinsCaspasesCell DeathHumansLungMitochondriaPhenforminProtein Serine-Threonine KinasesAMP-Activated Protein KinasesApoptosis Inducing FactorBone Morphogenetic ProteinsCaspasesPhenforminProtein Serine-Threonine KinasesAIFAMPKBMPCaspase-independentCell death

Identifiers

PMID35761398
PMCPMC9238106
OpenAlexW4283690436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.